Healthcare
NeoGenomics, Inc.(NEO)
Live Price
Offline$11.13
+7.23% today
1Y Change
+59.75%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $250.00M
- Revenue Growth
- +10.1%
- EPS Growth
- -35.5%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
NeoGenomics, Inc. (NEO) is a Healthcare stock with a market cap of $250.00M and listed on NASDAQ. The stock last traded around $11.13 and up 59.7% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +10.1%, EPS growth of -35.5%, a dividend yield of 0.0%. What stands out right now is revenue +10.1%, EPS -35.5%, free cash flow +36.0% with operating margin -13.9% and ROIC -8.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines NEO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.1% vs +7.6% peer median
Operating Margin
Below sector median
-13.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +10.1% and EPS is at -35.5%, with operating margin around -13.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +0.3% | -1.2% | +14.4% |
2026 Feb 17, 2026 | +50.0% | -10.3% | -15.6% | -27.7% |
2025 Oct 28, 2025 | +50.0% | +3.6% | +1.8% | +24.4% |
Benchmark Edge
NEO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NEO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NEO Max Drawdown
-45.61%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NEO and SPY.
Company Overview
NeoGenomics, Inc.
NASDAQ Capital Market
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
- Leadership
- Anthony Zook
- IPO Date
- Mar 16, 2004
- Employees
- 2.2k
- Street Address
- 9490 NeoGenomics Way
- Mailing
- Fort Myers, FL, 33912
- Region
- Fort Myers, FL, US
- Reporting Currency
- USD
- Investor Line
- 239 768 0600
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.3
- Price/Book
- 0.3
Growth
- Revenue
- +10.1%
- EPS
- -35.5%
- Free Cash Flow
- +36.0%
Profitability
- Gross Margin
- 42.1%
- Operating Margin
- -13.9%
- Net Margin
- -13.3%
- ROE
- -11.8%
- ROIC
- -8.0%
Balance Sheet
- Debt/Equity
- 0.49
- Current Ratio
- 4.42
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.